$299 Million is the total value of Euclidean Capital LLC's 13 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PMVP | PMV PHARMACEUTICALS INC | $137,461,000 | -46.5% | 4,179,416 | 0.0% | 45.99% | -15.5% | |
| NGM | Sell | NGM BIOPHARMACEUTICALS INC | $43,412,000 | -31.2% | 1,493,349 | -28.3% | 14.52% | +8.7% |
| ORIC | Sell | ORIC PHARMACEUTICALS INC | $24,420,000 | -48.5% | 996,734 | -28.8% | 8.17% | -18.6% |
| ALEC | ALECTOR INC | $19,755,000 | +33.1% | 980,894 | 0.0% | 6.61% | +110.4% | |
| DNLI | DENALI THERAPEUTICS INC | $18,486,000 | -31.8% | 323,749 | 0.0% | 6.18% | +7.7% | |
| FHTX | FOGHORN THERAPEUTICS INC | $16,623,000 | -35.0% | 1,261,261 | 0.0% | 5.56% | +2.8% | |
| RAPT | RAPT THERAPEUTICS INC | $16,335,000 | +12.4% | 735,801 | 0.0% | 5.46% | +77.7% | |
| CNST | CONSTELLATION PHARMCETICLS I | $12,966,000 | -18.8% | 554,325 | 0.0% | 4.34% | +28.3% | |
| FFBC | FIRST FINL BANCORP OH | $4,166,000 | +36.9% | 173,576 | 0.0% | 1.39% | +116.5% | |
| BEAM | New | BEAM THERAPEUTICS INC | $2,492,000 | – | 31,131 | +100.0% | 0.83% | – |
| VIR | New | VIR BIOTECHNOLOGY INC | $1,326,000 | – | 25,864 | +100.0% | 0.44% | – |
| PDD | New | PINDUODUO INCsponsored ads | $1,094,000 | – | 8,174 | +100.0% | 0.37% | – |
| RUBY | New | RUBIUS THERAPEUTICS INC | $339,000 | – | 12,791 | +100.0% | 0.11% | – |
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -93,436 | -100.0% | -0.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
| FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
| NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
| ALECTOR INC | 12 | Q3 2023 | 11.5% |
| RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
| TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
| FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
| SURROZEN INC | 9 | Q3 2023 | 2.9% |
| 23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2023-12-01 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.